Upacicalcet Sodium Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Upacicalcet Sodium Hydrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Upacicalcet Sodium Hydrate can convert its Small molecule drug profile and CaSR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Upacicalcet Sodium Hydrate (query alias: Upacicalcet Sodium Hydrate) |
|---|---|
| Modality / target | Small molecule drug; CaSR; CaSR modulators |
| Highest global status | Approved |
| Originator | Sanwa Kagaku Kenkyusho Co., Ltd. |
| Active developers | Pathalys Pharma, Inc., Tasly Pharmaceutical Group Co., Ltd., EA Pharma Co., Ltd. |
The MCP disease footprint includes Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Hyperparathyroidism. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05836220 | Phase 3 | Completed | 412 | The proportion of PLS240 treated participants compared to the portion of placebo treated participants with a ≥30% decrease in mean iPTH |
| NCT05832931 | Phase 3 | Completed | 362 | Double-Blind Phase: Proportion of PLS240 treated participants compared to placebo treated participants with a ≥30% decrease in mean iPTH |
| JPRN-jRCTs041220126 | Not Applicable | Not Recruiting | 350 | The amount of change in log-transformed CACS (volume) from baseline (observation period) to 52 weeks (12 months) after study treatment. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Long-term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-label 52-week Study
; n=157; evaluation: 积极. Reported fields: iPTH(60-240 pg-mL，52-week) = 94.2 %
Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism
Phase 3; n=103; evaluation: Positive. Reported fields: Mean serum iPTH concentration = 8 % ; Mean serum iPTH concentration = 67 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Upacicalcet Sodium Hydrate addresses Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Hyperparathyroidism. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2022-03-01 | EA Pharma Signed a Worldwide License Agreement of AJT240, a Treatment for Secondary Hyperparathyroidism, with Pathalys Pharma, Inc. except Japan, Korea, China, Taiwan and ASEAN Countries | Approved | Financial terms not disclosed |
| 2018-06-11 | Tasly and EA Pharma collaborate on the development and commercialization of AJT-240 for treating secondary hyperparathyroidism in the People's Republic of China. | Phase 2 | US$24.0M stated total |
| 2017-10-31 | EA Pharma Signed a License Agreement with JW Pharmaceutical for Secondary Hyperparathyroidism Treatment AJT240 | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
